RT Journal Article
SR Electronic
T1 Reduced neutralizing activity of post-SARS-CoV-2 vaccination serum against variants B.1.617.2, B.1.351, B.1.1.7+E484K and a sub-variant of C.37
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.07.21.21260961
DO 10.1101/2021.07.21.21260961
A1 Juan Manuel Carreño
A1 Hala Alshammary
A1 Gagandeep Singh
A1 Ariel Raskin
A1 Fatima Amanat
A1 Angela Amoako
A1 Ana Silvia Gonzalez-Reiche
A1 Adriana van de Guchte
A1 PARIS study group
A1 Mahmoud Awawda
A1 Radhika Banu
A1 Katherine Beach
A1 Carolina Bermúdez-González
A1 Dominika Bielak
A1 Liyong Cao
A1 Rachel Chernet
A1 Parnavi Desai
A1 Shelcie Fabre
A1 Emily. D. Ferreri
A1 Daniel Floda
A1 Charles Gleason
A1 Hisaaki Kawabata
A1 Zenab Khan
A1 Giulio Kleiner
A1 Denise Jurczyszak
A1 Julia Matthews
A1 Wanni Mendez
A1 Lubbertus CF Mulder
A1 Kayla Dr. Alberto E Paniz-Mondolfi
A1 Russo
A1 Ashley Salimbangon
A1 Miti Saksena
A1 A. Shin
A1 Levy Sominsky
A1 Johnston Tcheou
A1 Komal Srivastava
A1 Emilia Mia Sordillo
A1 D. Noah Sather
A1 Harm van Bakel
A1 Florian Krammer
A1 Viviana Simon
YR 2021
UL http://medrxiv.org/content/early/2021/07/23/2021.07.21.21260961.abstract
AB Highly efficacious vaccines against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) have been developed.1 However, the emergence of viral variants that are more infectious than the earlier SARS-CoV-2 strains is concerning.2 Several of these viral variants have the potential to partially escape neutralizing antibody responses warranting continued immune-monitoring. Here, we tested a number of currently circulating viral variants of concern/interest, including B.1.526 (Iota), B.1.1.7+E484K (Alpha), B.1.351 (Beta), B.1.617.2 (Delta) and C.37 (Lambda) in neutralization assays using a panel of post-mRNA vaccination sera. The assays were performed with authentic SARS-CoV-2 clinical isolates in an assay that mimics physiological conditions. We found only small decreases in neutralization against B.1.526 and an intermediate phenotype for B.617.2. The reduction was stronger against a sub-variant of C.37, followed by B.1.351 and B.1.1.7+E484K. C.37 is currently circulating in parts of Latin America3 and was detected in Germany, the US and Israel. Of note, reduction in a binding assay that also included P.1, B.1.617.1 (Kappa) and A.23.1 was negligible. Taken together, these findings suggest that mRNA SARS-CoV-2 vaccines may remain effective against these viral variants of concern/interest and that spike binding antibody tests likely retain specificity in the face of evolving SARS-CoV-2 diversity.Competing Interest StatementThe Icahn School of Medicine at Mount Sinai has filed patent applications relating to SARS-CoV-2 serological assays and NDV-based SARS-CoV-2 vaccines which list Florian Krammer as co-inventor. Viviana Simon and Fatima Amanat are also listed on the serological assay patent application as co-inventors. Mount Sinai has spun out a company, Kantaro, to market serological tests for SARS-CoV-2. Florian Krammer has consulted for Merck and Pfizer (before 2020), and is currently consulting for Pfizer, Seqirus and Avimex. The Krammer laboratory is also collaborating with Pfizer on animal models of SARS-CoV-2.  Clinical Trialnot applicableFunding StatementThis work is part of the PARIS/SPARTA studies funded by the NIAID Collaborative Influenza Vaccine Innovation Centers (CIVIC) contract 75N93019C00051. This work was also partially funded by the Centers of Excellence for Influenza Research and Surveillance (CEIRS, contract # HHSN272201400008C), and by the generous support of the JPB Foundation and the Open Philanthropy Project (research grant 2020-215611 (5384); and by anonymous donors. Finally, this effort was also supported by the Serological Sciences Network (SeroNet) in part with Federal funds from the National Cancer Institute, National Institutes of Health, under Contract No. 75N91019D00024, Task Order No. 75N91020F00003. The content of this publication does not necessarily reflect the views or policies of the Department of Health and Human Services, nor does mention of trade names, commercial products or organizations imply endorsement by the U.S. Government.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The PARIS (Protection Associated with Rapid Immunity to SARS-CoV-2) study was reviewed and approved by the Mount Sinai Hospital Institutional Review Board; IRB-20-03374All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data referred to in the manuscript are available